

BCMAS Program:

An Overview For Scientific & Clinical Professionals

William Soliman, PhD, MPhil, MA
Founder, President/CEO
The Apotheker Group




Conflicts of Interest/Disclosures

- Shareholder
 - Zafgen Inc.
 - Gilead Sciences
 - Veeva
 - Retrophin
- Consultant
 - Third Bridge Consulting LLC
 - Atheneum Partners Life Sciences Consulting LLC
 - Bain & Company LLC
 - Retrophin Pharmaceuticals
- Scientific Industry Advisor
 - AlphaSights LLC
 - GLG Consulting LLC
 - L.E.K. Consulting LLC
 - Medmeme Incorporated
- Principal
 - US Pharmacy Lab
 - Science Gladiators LLC
 - Accreditation Council for Medical Affairs


Disclaimer

The views and opinions expressed in this presentation and on the following slides are solely my own and not necessarily those of any companies, academic institutions or organizations I am currently affiliated or have been affiliated with previously.

Drug Industry Revenue




Emerging New Markets




Source: http://www.fiercebiotech.com/story/amgen-gets-big-win-fda-ok-pcsk9-drug-repatha/2015-08-27

Mergers and Acquisitions



Shift to Specialty Drugs



Small molecule Large population

Cardiovascular

Biologic Small population


Rheumatoid Arthritis

Biologic Large population

Cardiovascular

Source: http://www.fiercebiotech.com/story/amgen-gets-big-win-fda-ok-pcsk9-drug-repatha/2015-08-27

Skyrocketing Drug Development Costs




\$2.6 billion cost to bring one prescription drug to market today*


How prepared are you?

When a PharmD, PhD and/or an MD isn't enough...


Subject Matter & Technical Expertise are Expected...Now what?




Who is the Effective Medical/Clinical Professional?



Pharmaceutical Industry Overview



Pharmaceutical Industry Overview



Medical Affairs is Growing

1967

Upjohn coins the term Medical Science Liaison in support of external researchers 300%

Growth in the number of MSL's deployed from 2001 to 2020

49%

Physicians placing moderate to severe restrictions on visits

2009

Phrma guidelines take effect – permanently changing scientific communication **79%**

Of companies see medical affairs budgets increasing by more than 10% year over year

20

Average number of patients see per day

400 billion


Spend on Specialty Care drugs by 2020

495

Compounds for Rare Diseases are currently under review 24%


Of new approvals in 2014 were for biologics

MSLs are in the Middle of the Scientific Continuum




Adapted from: Lev R, Winter-Sperry R. Off-label promotion vs. scientific exchange: Ensure effective and compliant medical affairs communication


Influence of Stakeholders has Changed



Evolution of Physician Engagement



Medical Affairs by Degree: Increasing Competition



Board Certification Program in Medical Affairs (BCMAS)

- What is it?
 - The BCMAS program is the only board certification program developed by the the Accreditation Council for Medical Affairs (ACMA) in conjunction with the Apotheker Group.
 - It is the most comprehensive medical affairs program in the industry.



Who is Eligible?

- To be eligible for the program, you must meet the criteria below:
 - MD or DO, PhD, or PharmD Professional OR
 - Student enrolled in an accredited academic doctoral program*
 - MD
 - PharmD
 - PhD
 - DO



Jennifer Smith, PharmD, BCMAS



BCMAS Program

- The program consists of 20 Different Modules
- A final exam with at least an 80% passing rate is required to achieve board certification.
 - The exam consists of approximately 90 questions.
 - It is offered worldwide via Online Proctoring by a testing provider.
- The entire program is Online & Self-Paced
- Maintenance Required (Recertification every 5 years)





Areas of Focus- Some Highlights

- Twenty Modules in Total Covering a variety of important concepts in medical affairs including:
 - Rules Governing Interactions with Health Care Providers
 - Health Economics Outcomes Research
 - Evidence Based Medicine & Clinical Trial Designs
 - Regulatory Affairs & Compliance
 - Medical Device & Diagnostics Industries
 - Medical Science Liaisons & Medical Information
 - REMS & Pharmacovigilance







Advisors/Contributors to BCMAS Development





RUTGERS

Ernest Mario School of Pharmacy



School of Pharmacy





Paul Rowe, MD Vice President, Medical Affairs, Sanofi

- Jim Alexander, PharmD
 Founder, Executive VP, Industry Pharmacists
 Organization (IPHO)
- Richard Eschle, PharmD, JD
 Executive Director, Corporate Ethics & Compliance, Eisai Pharmaceuticals Inc.
- Sam Rasty, PharmD, BCPS, MPH
 Associate Professor of Clinical Pharmacy, California Northstate University, former Global Regulatory Intelligence at Takeda Pharmaceuticals
- Albert Rego, PhD Scientific/Regulatory Consultant, Albert Rego Inc.
- Wava Truscott, PhD, MBA
 Truscott MedSci Associates, Dir. Medical Sciences/Clinical Education Kimberly-Clark HealthCare

Anthony Bevilacqua, PharmD Senior Medical Science Liaison Eisai Pharmaceuticals Inc. Tiffany Marsh, PharmD, MBA

Senior MSL Trainer, Medical Affairs, Skills & Education, Sanofi

Mehul Patel, PharmD

Medical Director, Medical Affairs, Allergan

Michael Toscani, PharmD

Fellowship Director, Research Professor, Rutgers Institute for Pharmaceutical Industry Fellowships, Rutgers University

Tina Kanmaz, PharmD

Assistant Dean for Experiential Pharmacy Education St. John's University College of Pharmacy

Anna Dushenkov, PharmD

Assistant Professor, Pharmacy Practice FDU School of Pharmacy

Raghda Abdelnabi, EdD, BPharm

Curriculum/Pedagogical & Assessment Consultant















Thank You

Contact Information:

wsoliman@apothekergroup.com

Visit: www.apothekergroup.com

For more information about the **BCMAS** Program visit:

www.medicalaffairsspecialist.org

